Cancer Res Treat.  2025 Jan;57(1):28-38. 10.4143/crt.2024.325.

Trends in Cancer-Screening Rates in Korea: Findings from the National Cancer Screening Survey, 2004-2023

• Kang E
• Choi KS
• Jun JK
• Kim Y
• Lee HJ
• Choi CK
• Kim TH
• Lee SH
• Suh M

• KMID: 2564578
• DOI: http://doi.org/10.4143/crt.2024.325

Abstract

Purpose
This study aimed to report the overall national trends in the rates of cancer screening based on recommendations and provide insights into the changing trends of these rates across different demographics.
Materials and Methods
This study used data from the Korean National Cancer Screening Survey (KNCSS), which surveys nationwide cancer-screening rates and includes 4,500 individuals meeting the Korean National Cancer Screening Program (NCSP) protocol age criteria. Cancer-screening rates were assessed using structured questionnaires; yearly trends were analyzed for both lifetime cancer-screening rates and rates of screening based on recommendations, and subgroup analyses were performed based on age and sex.
Results
The rates of cancer screening based on recommendations showed significant increments: the stomach cancer-screening rate increased from 39.2% in 2004 to 77.5% in 2023 (3.50% per year), the liver cancer-screening rate increased from 20.0% to 48.8% (4.30% per year), and the colorectal cancer, increased from 19.9% to 70.7% (5.15% per year). The breast cancer-screening rate increased from 33.2% to 72.7% (2.88% per year), and the cervical cancer, increased from 58.3% to 70.2% (1.08% per year). Despite some differences, particularly in relation to sociodemographic factors, screening rates increased significantly for all cancer types.
Conclusion
Cancer-screening rates in Korea increased consistently from 2004 to 2023, demonstrating the effectiveness of the national cancer-screening program. However, the increments in breast, cervical and lung cancer-screening rates were relatively lower, indicating the need for additional efforts and strategies.

Keyword

Early detection of cancer; Mass screening; Health care surveys; Trends; Stomach neoplasms; Colorectal neoplasms; Liver neoplasms; Breast neoplasms; Uterine cervical neoplasms; Lung neoplasms

Figure

• 

  Fig. 1. Trends in cancer screening rates with recommendation by sex, from 2004 to 2023: stomach cancer (A) and colorectal cancer (B).

• 

  Fig. 2. Trends in cancer screening rates with recommendation by age group, from 2004 to 2023: stomach cancer (A), colorectal cancer (B), breast cancer (C), and cervical cancer (D).

• 

  Fig. 3. The sources of cancer-screening costs, from 2004 to 2023.

Reference

References

1. Kim YA, Lee YR, Park J, Oh IH, Kim H, Yoon SJ, et al. Socioeconomic burden of cancer in Korea from 2011 to 2015. Cancer Res Treat. 2020; 52:896–906.

2. Kim YE, Park H, Jo MW, Oh IH, Go DS, Jung J, et al. Trends and patterns of burden of disease and injuries in Korea using disability-adjusted life years. J Korean Med Sci. 2019; 34:e75.

3. Kang MJ, Jung KW, Bang SH, Choi SH, Park EH, Yun EH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020. Cancer Res Treat. 2023; 55:385–99.

4. Kim KW, Kim OS. Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr. 2020; 8:155–73.

5. Oh CM, Lee D, Kong HJ, Lee S, Won YJ, Jung KW, et al. Causes of death among cancer patients in the era of cancer survivorship in Korea: attention to the suicide and cardiovascular mortality. Cancer Med. 2020; 9:1741–52.

6. Lee J, Kim Y, Kim HY, Goo JM, Lim J, Lee CT, et al. Feasibility of implementing a national lung cancer screening program: interim results from the Korean Lung Cancer Screening Project (K-LUCAS). Transl Lung Cancer Res. 2021; 10:723–36.

7. Wild CP. The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer. 2019; 19:123–4.

8. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021; 116:458–79.

9. Weller DP, Elfstrom KM. Commentary: back to the future in cervical screening: applying a contemporary lens to an old controversy. J Clin Epidemiol. 2020; 127:218–9.

10. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019; 69:184–210.

11. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:229–63.

12. Islami F, Guerra CE, Minihan A, Yabroff KR, Fedewa SA, Sloan K, et al. American Cancer Society’s report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin. 2022; 72:112–43.

13. Hong S, Lee YY, Lee J, Kim Y, Choi KS, Jun JK, et al. Trends in cancer screening rates among Korean men and women: results of the Korean National Cancer Screening Survey, 2004-2018. Cancer Res Treat. 2021; 53:330–8.

14. Surveillance Research Program: Joinpoint trend analysis software, version 5.0.2 [Internet]. Bethesda, MD: National Cancer Institute;2023. 2023 [cited 2023 Jul 16]. Available from: https://surveillance.cancer.gov/joinpoint/.

15. Mabe K, Inoue K, Kamada T, Kato K, Kato M, Haruma K. Endoscopic screening for gastric cancer in Japan: current status and future perspectives. Dig Endosc. 2022; 34:412–9.

16. Suh YS, Lee J, Woo H, Shin D, Kong SH, Lee HJ, et al. National cancer screening program for gastric cancer in Korea: Nationwide treatment benefit and cost. Cancer. 2020; 126:1929–39.

17. Jun JK, Choi KS, Lee HY, Suh M, Park B, Song SH, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology. 2017; 152:1319–28.

18. Cho YH, Kim DH, Cha JM, Jeen YT, Moon JS, Kim JO, et al. Patients’ preferences for primary colorectal cancer screening: a survey of the National Colorectal Cancer Screening Program in Korea. Gut Liver. 2017; 11:821–7.

19. Park B, Her EY, Lee K, Nari F, Jun JK, Choi KS, et al. Overview of the National Cancer Screening Program for colorectal cancer in Korea over 14 years (2004-2017). Cancer Res Treat. 2023; 55:910–7.

20. National Cancer Institute cancer trends progress reports: breast cancer screening [Internet]. Bethesda, MD: National Cancer Institute;2022. [cited 2023 Jul 15]. Available from: https://progressreport.cancer.gov/detection/breast_cancer#:~:text=Increase%20to%2077.1%20percent%20the%20proportion%20of%20women,cancer%20screening%20based%20on%20the%20most%20recent%20guidelines.

21. Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncol. 2020; 21:1165–72.

22. NHS Breast screening programme, England 2021-22 [Internet]. Leeds: NHS England;2022. [cited 2023 Jul 15]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme/england---2021-22/introduction; 2021-22.

23. Choi E, Jun JK, Suh M, Jung KW, Park B, Lee K, et al. Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality. NPJ Breast Cancer. 2021; 7:83.

24. National Cancer Institute cancer trends progress reports: cervical cancer screening [Internet]. Bethesda, MD: National Cancer Institute;2022. [cited 2023 Jul 14]. Available from: https://progressreport.cancer.gov/detection/cervical_cancer.

25. Choi S, Ismail A, Pappas-Gogos G, Boussios S. HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens. 2023; 12:298.

26. Cervical screening programme, England 2021-2022 [Internet]. Leeds: NHS England;2022. [cited 2023 Jul 15]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-annual/england-2021-2022.

27. Watson M, Benard V, Flagg EW. Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014. Prev Med Rep. 2018; 9:124–30.

28. Suk R, Hong YR, Rajan SS, Xie Z, Zhu Y, Spencer JC. Assessment of US Preventive Services Task Force guideline-concordant cervical cancer screening rates and reasons for underscreening by age, race and ethnicity, sexual orientation, rurality, and insurance, 2005 to 2019. JAMA Netw Open. 2022; 5:e2143582.

29. Kim W, Chun S, Lee SA. Changes in cervical dysplasia, carcinoma in situ, and cervical cancer after expanding the National Cancer Screening Program to younger women in Korea. Int J Qual Health Care. 2023; 35:mzad024.

30. Williams RM, Li T, Luta G, Wang MQ, Adams-Campbell L, Meza R, et al. Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data. Cancer. 2022; 128:1812–9.

31. Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, et al. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force. JAMA. 2021; 325:988–97.

32. Community Preventive Services Task Force findings [Internet]. Atlanta, GA: The Community Guide;2022. [cited 2023 Jul 15]. Available from: https://thecommunityguide.org/pages/task-force-findings.html.

33. Bakker EA, Hartman YA, Hopman MT, Hopkins ND, Graves LE, Dunstan DW, et al. Validity and reliability of subjective methods to assess sedentary behaviour in adults: a systematic review and meta-analysis. Int J Behav Nutr Phys Act. 2020; 17:75.